newsfilter
← Latest News
GlobeNewswire·

Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023

Phase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022 Phase 1 trial in glaucoma expected to commence in first quarter of 2023 Acquired corneal gene therapy program; Phase 1/2a data expected in fourth quarter o